Afoxolaner

Marketing

List of excipients">Excipient">excipients

• Maize starch
• Soy protein fines
• Beef braised flavouring
• Povidone
• Macrogol 400
• Macrogol 4000
• Macrogol 15 hydroxystearate
• Glycerol
• Triglycerides, medium-chain

• Citric acid monohydrate
• Butylated hydroxytoluene

  Safety

Dosage

Toxicity for mammals

• The oral toxicity profile of afoxolaner consists of a diuretic effect, effects secondary to a reduction in food consumption and occasional vomiting and/or diarrhoea following high oral doses. No treatment-related effects on vomiting or diarrhoea were noted following oral doses of up to 31.5 mg/kg bw in the pivotal target animal safety study, nor in the EU field trial.
• mild gastrointestinal effects, pruritus, lethargy, anorexia, and neurological signs have been reported in less than 0.1% of 10,000 animals treated, including isolated reports, most reported adverse reactions being self-limiting and of short duration,
• : vomiting, diarrhoea, lethargy, anorexia, and pruritus were observed in 0.2 to 1% of 10,000 animals treated and were generally self-limiting and of short duration,
• In vitro studies reported that afoxolaner can bind to dopamine and norepinephrine cellular transport receptor systems and the CB1 receptor; inhibition of these catecholaminergic systems and certain types of competitive binding at CB1 receptors may mediate pharmacodynamic effects of diuresis, decreased food consumption, and decreased body weight in animals.

• : erythema and neurological signs have been reported in less than 0.1% of 10,000 animals treated, including isolated reports,
• The US FDA reports that some drugs in this class, including afoxalaner, can have adverse neurologic effects on some dogs, such as muscle tremors, ataxia, and seizures.
• Extralabel use of afoxolaner in a pet pig has been described without any adverse effects. Experimental use in commercial pigs also did not result in any adverse effects.

  Selectivity insects over mammalians